Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial - Seite 3

ⁱ Garin-Chesa P et al. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87(18):7235-9.
ⁱⁱ Park JE et al. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 1999;274(51):36505-12.
ⁱⁱⁱ Rettig WJ et al. Regulation and Heteromeric Structure of the Fibroblast Activation Protein in Normal and Transformed Cells of Mesenchymal and Neuroectodermal Origin. Cancer Res. 1993;53:3327–3335.
^iv Yong KJ et al. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from ¹⁷⁷Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenograpfts. Int. J. of Mol.Sci. 2016; 17: 736.
^v Zboralski, D et al. Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP). European Society for Medical Oncology (ESMO) Congress 2020. 18-22 September 2020. Madrid, Spain.
^vi Grzmil M, Meisel A, Behé M., Schibli R. (2019) An Overview of Targeted Radiotherapy. In: Lewis J., Windhorst A., Zeglis B. (eds) Radiopharmaceutical Chemistry. Springer, Cham.
^vii National Research Council 2007. Advancing Nuclear Medicine Through Innovation. Washington, DC: The National Academies Press. https://doi.org/10.17226/11985.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201229005036/en/